Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)

Introduction Acute gastroenteritis is one of the most common causes of children’s morbidity and mortality globally. Oral or intravenous rehydration was proven effective in reducing the mortality rates in acute gastroenteritis, although it does not affect the course of the disease. Attempts to identi...

Full description

Bibliographic Details
Main Authors: Katarzyna Wzorek-Łyczko, Anna Piwowarczyk, Ernest Kuchar
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/3/e042370.full
id doaj-27f8efd0abb2466f9961915278bd8127
record_format Article
spelling doaj-27f8efd0abb2466f9961915278bd81272021-07-02T13:04:29ZengBMJ Publishing GroupBMJ Open2044-60552021-03-0111310.1136/bmjopen-2020-042370Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)Katarzyna Wzorek-Łyczko0Anna Piwowarczyk1Ernest Kuchar2The Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, PolandThe Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, PolandThe Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, PolandIntroduction Acute gastroenteritis is one of the most common causes of children’s morbidity and mortality globally. Oral or intravenous rehydration was proven effective in reducing the mortality rates in acute gastroenteritis, although it does not affect the course of the disease. Attempts to identify new therapeutic methods effective in reducing the symptoms of diarrhoea are of interest. Pleuran’s potential immunomodulatory effect in acute gastrointestinal infection relies on the stimulation of innate immunity. The effectiveness of pleuran (β-(1,3/1,6)-d-glucan) administration to treat acute infectious diarrhoea remains unknown. This study evaluates the efficacy of pleuran in reducing diarrhoea duration and the severity of acute gastroenteritis symptoms in children.Methods and analysis Our study is a randomised, double-blind, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio. A total of 120 children aged 2–10 years hospitalised or requiring a visit to the emergency department because of acute gastroenteritis will be randomly assigned to receive either pleuran oral suspension in the experimental group or matching placebo in the control group. The primary outcome measure will be the duration of diarrhoea. We will analyse the results in both intention-to-treat and per-protocol approaches.Ethics and dissemination The Bioethics Committee of The Medical University of Warsaw approved the study protocol (approval number: KB/45/2018). Written informed consent of the patients’ caregivers participating in the study will be obligatory. The results of this study will be published in a medical journal, regardless of whether they confirm or deny the research hypothesis.Trial registration number NCT03988257; Pre-results.https://bmjopen.bmj.com/content/11/3/e042370.full
collection DOAJ
language English
format Article
sources DOAJ
author Katarzyna Wzorek-Łyczko
Anna Piwowarczyk
Ernest Kuchar
spellingShingle Katarzyna Wzorek-Łyczko
Anna Piwowarczyk
Ernest Kuchar
Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)
BMJ Open
author_facet Katarzyna Wzorek-Łyczko
Anna Piwowarczyk
Ernest Kuchar
author_sort Katarzyna Wzorek-Łyczko
title Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)
title_short Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)
title_full Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)
title_fullStr Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)
title_full_unstemmed Protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (EPTAGE)
title_sort protocol of the study: the effectiveness of pleuran in the treatment of acute gastroenteritis in children—a randomised, placebo-controlled, double-blind trial (eptage)
publisher BMJ Publishing Group
series BMJ Open
issn 2044-6055
publishDate 2021-03-01
description Introduction Acute gastroenteritis is one of the most common causes of children’s morbidity and mortality globally. Oral or intravenous rehydration was proven effective in reducing the mortality rates in acute gastroenteritis, although it does not affect the course of the disease. Attempts to identify new therapeutic methods effective in reducing the symptoms of diarrhoea are of interest. Pleuran’s potential immunomodulatory effect in acute gastrointestinal infection relies on the stimulation of innate immunity. The effectiveness of pleuran (β-(1,3/1,6)-d-glucan) administration to treat acute infectious diarrhoea remains unknown. This study evaluates the efficacy of pleuran in reducing diarrhoea duration and the severity of acute gastroenteritis symptoms in children.Methods and analysis Our study is a randomised, double-blind, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio. A total of 120 children aged 2–10 years hospitalised or requiring a visit to the emergency department because of acute gastroenteritis will be randomly assigned to receive either pleuran oral suspension in the experimental group or matching placebo in the control group. The primary outcome measure will be the duration of diarrhoea. We will analyse the results in both intention-to-treat and per-protocol approaches.Ethics and dissemination The Bioethics Committee of The Medical University of Warsaw approved the study protocol (approval number: KB/45/2018). Written informed consent of the patients’ caregivers participating in the study will be obligatory. The results of this study will be published in a medical journal, regardless of whether they confirm or deny the research hypothesis.Trial registration number NCT03988257; Pre-results.
url https://bmjopen.bmj.com/content/11/3/e042370.full
work_keys_str_mv AT katarzynawzorekłyczko protocolofthestudytheeffectivenessofpleuraninthetreatmentofacutegastroenteritisinchildrenarandomisedplacebocontrolleddoubleblindtrialeptage
AT annapiwowarczyk protocolofthestudytheeffectivenessofpleuraninthetreatmentofacutegastroenteritisinchildrenarandomisedplacebocontrolleddoubleblindtrialeptage
AT ernestkuchar protocolofthestudytheeffectivenessofpleuraninthetreatmentofacutegastroenteritisinchildrenarandomisedplacebocontrolleddoubleblindtrialeptage
_version_ 1721329304032247808